Cargando…
Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study
Objective: To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acute pelvic infections. Methods: In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/po...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852268/ https://www.ncbi.nlm.nih.gov/pubmed/12839630 http://dx.doi.org/10.1155/S1064744903000048 |
_version_ | 1782133021076357120 |
---|---|
author | Roy, Subir Higareda, Iliana Angel-Muller, Edith Ismail, Mahmoud Hague, Caren Adeyi, Ben Woods, Gail L. Teppler, Hedy |
author_facet | Roy, Subir Higareda, Iliana Angel-Muller, Edith Ismail, Mahmoud Hague, Caren Adeyi, Ben Woods, Gail L. Teppler, Hedy |
author_sort | Roy, Subir |
collection | PubMed |
description | Objective: To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acute pelvic infections. Methods: In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then randomized to ertapenem, 1 g once a day, or piperacillin–tazobactam, 3.375 g every 6 hours, both administered intravenously. Results: In total, 163 patients in the ertapenem group and 153 patients in the piperacillin–tazobactam group were clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection. The frequency and severity of drug-related adverse events were generally similar in both groups. Conclusions: In this study, ertapenem was as effective as piperacillin–tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin–tazobactam. |
format | Text |
id | pubmed-1852268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-18522682007-04-16 Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study Roy, Subir Higareda, Iliana Angel-Muller, Edith Ismail, Mahmoud Hague, Caren Adeyi, Ben Woods, Gail L. Teppler, Hedy Infect Dis Obstet Gynecol Research Article Objective: To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acute pelvic infections. Methods: In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then randomized to ertapenem, 1 g once a day, or piperacillin–tazobactam, 3.375 g every 6 hours, both administered intravenously. Results: In total, 163 patients in the ertapenem group and 153 patients in the piperacillin–tazobactam group were clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection. The frequency and severity of drug-related adverse events were generally similar in both groups. Conclusions: In this study, ertapenem was as effective as piperacillin–tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin–tazobactam. Hindawi Publishing Corporation 2003 /pmc/articles/PMC1852268/ /pubmed/12839630 http://dx.doi.org/10.1155/S1064744903000048 Text en Copyright © 2003 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Roy, Subir Higareda, Iliana Angel-Muller, Edith Ismail, Mahmoud Hague, Caren Adeyi, Ben Woods, Gail L. Teppler, Hedy Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study |
title | Ertapenem Once a Day Versus Piperacillin–Tazobactam Every
6 Hours for Treatment of Acute Pelvic Infections:
A Prospective, Multicenter, Randomized, Double-Blind Study |
title_full | Ertapenem Once a Day Versus Piperacillin–Tazobactam Every
6 Hours for Treatment of Acute Pelvic Infections:
A Prospective, Multicenter, Randomized, Double-Blind Study |
title_fullStr | Ertapenem Once a Day Versus Piperacillin–Tazobactam Every
6 Hours for Treatment of Acute Pelvic Infections:
A Prospective, Multicenter, Randomized, Double-Blind Study |
title_full_unstemmed | Ertapenem Once a Day Versus Piperacillin–Tazobactam Every
6 Hours for Treatment of Acute Pelvic Infections:
A Prospective, Multicenter, Randomized, Double-Blind Study |
title_short | Ertapenem Once a Day Versus Piperacillin–Tazobactam Every
6 Hours for Treatment of Acute Pelvic Infections:
A Prospective, Multicenter, Randomized, Double-Blind Study |
title_sort | ertapenem once a day versus piperacillin–tazobactam every
6 hours for treatment of acute pelvic infections:
a prospective, multicenter, randomized, double-blind study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852268/ https://www.ncbi.nlm.nih.gov/pubmed/12839630 http://dx.doi.org/10.1155/S1064744903000048 |
work_keys_str_mv | AT roysubir ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy AT higaredailiana ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy AT angelmulleredith ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy AT ismailmahmoud ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy AT haguecaren ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy AT adeyiben ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy AT woodsgaill ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy AT tepplerhedy ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy |